The first segment is Synthetic Biology. This is what I call the Mail Order DNA business. Many companies need DNA for developing therapies like cell engineering or gene therapies. Many of these DNA strands can be synthesized for just a few cents per base.
This won't be a huge money maker as they can ship hundreds of thousands of DNA sequences a year for just a few dollars per. It is the back bone of their sales, and its still growing nicely. Its the cash cow that will fund the future developments which can be big winners.
The next segment is the Next Generation Sequencing space. They build the kits and test for use in PCR. These are the test kits for use in oncology, infectious disease and MRD. This is another commercial business that does not have huge potential, but it does make money.
The first big space where $TWST can take themselves from a small company to a mega cap someday is their Biopharma. They have a massive library of DNA sequencing. They are leveraging all their technology to help companies develop antibodies.
They currently have 81 project underway and continue to develop new partnerships as they go. They will earn milestones and royalties on many of these programs. The more successful their partners become the more royalties they will earn.
Even just one successful program in this segment could earn more revenues then both the Synbio and NGS segments combined. There is a lot of potential in this space. This is the reason I own $TWST for the long term.
All the commercial sales they have now go to funding the segments of the future that could take this company to the next level.
The last segment is the DNA storage. This is about turning the 1's and 0's of computer storage into A's, T's, G's and C's. The potential for DNA to store massive amounts of data into a space so small it can't be even seen with the eye is huge.
Right now they have a chip for DNA storage in the Gigabyte scale working toward a Terabyte chip. There is a huge amount of interest for long term low cost storage.
• • •
Missing some Tweet in this thread? You can try to
force a refresh
When I look at $DNA, I see 2 companies with the #Synbio side and the #Biosecurity. I know many people dismiss the biosecurity which is over 50% of the current revenues. They mostly come from Covid screening. You got to think that a cut in funding will impact these sales.
In the long term, I think biosecurity is a key strategy as $DNA is one of the only companies working on solutions to a problem that is being completely ignored. The biggest threat to the global economy is now bioterrorism.
Although Biosecurity revenues in the near term might come under pressure, I think the need for them will grow over time. Not for just monitoring infectious disease, but as a security measure to our way of life.
I only got 2 companies for my play on Personalized Medicine. This is about using genetic information to develop better therapies for patients. The 2 companies I want to look at are $NVTA and $EXAI.
$EXAI is really exciting. Beside having an #AI based drug development platform, they also have a single cell biopsy program. They take a single cell from the tumor and sequence it.
This gives them the information on which patients will have the best responses from which drugs. This is about Pharmacogenomics. How different people respond differently to medications based on their genetics.
I am going to mention a few more #CRISPR companies that didn't meet my expectations to be in my portfolio. My next pick would actually be $VERV. I have some reservations on how much market share they could really capture in an extremely competitive space of Cholesterol.
$VERV has impressed me on the management front. There is noting I would bet on more then top notch management. A great CEO will make magic out of nothing. I think $VERV with base editing and a great CEO will be successful, I just don't know how successful.
Then comes $CRSP which use to be my first and only #CRISPR company. I completely changes on this company. They have a great SCD program what will be successful, but it ends there.
My 3rd #CRISPR company has to be $CRBU, even though, I count them in my cell therapies space. They are not focused on any in-vivo editing at this time. They are completely focused on cell therapies around CAR-T and NK cells.
They are using the CAS9 and CAS12 enzymes along with their own unique guide called chRDNA. This uses a combination of RNA and DNA in the guide to increase binding affinity and better editing.
Their early data this week for CAR-T was impressive. It is still very early and clearly PD-1 will not be the "be all to end all". There are a lot of challenges to allogeneic CAR-T that need to be solved.
My second pick for #CRISPR is $NTLA. I know they are on the losing side of the patent dispute. We still don't know what if any impact that will have. They do have a great management team that is building a great company.
They are using first generation CAS9 editing in-vivo in the liver and for ex-vivo for cell therapies. They are also developing their own base editing program. They are still ambitious and chasing innovation. That is what gets my vote.
They have best in class data in their early ATTR program in phase 1. Its got a long way to go, but could be a huge success if this data continues. They have about $1 billion in cash to get them through this bear market in biotech.
$BEAM is my top pick in the #CRISPR space. They have base editing which solves many of the issues with the first generation editors. They still have the CAS12 if they need it to do any cell editing in their cell therapies.
All their tech licenses comes from the winning side of the patent dispute which makes them safe. They have a great management team. They also have $1.2 billion in cash which will last them a long time in this bear market.
They are just entering the clinic this year so it will all come down to the data. Their preclinical data seemed superior to that of $CRSP at the same stage of development.